New data shows superior viral suppression for Triumeq in women with HIV
pharmafile | July 18, 2016 | News story | Manufacturing and Production, Research and Development | Triumeq, ViiV Healthcare
ViiV Healthcare has presented late-stage data showing superior efficacy for combination treatment Triumeq (dolutegravir/abacavir/lamivudine) compared with atazanavir, plus other treatments, in treatment-naïve women living with HIV.
Triumeq is a once-daily dolutegravir-based regimen, containing the unboosted integrase strand transfer inhibitor dolutegravir and the nucleoside reverse transcriptase inhibitors abacavir and lamivudine. The latter two help to prevent the HIV virus from replicating.
ViiV, a spinout of GSK and Pfizer, recorded statistically superior viral suppression rates after 48 weeks in the Triumeq versus atazanvir boosted by antiretrovirals, with 82% versus 71% respectively, in 495 treatment-naïve women living with HIV.
Interestingly, despite infection rates of HIV in young women being twice that seen in young men, women have been routinely underrepresented in clinical trials for HIV treatments. As such there is a lack of knowledge about issues regarding antiretroviral treatments that are particular to women.
John Pottage, chief medical officer at ViiV, says: “For this reason, we are committed to ensuring that the specific treatment needs of women are investigated. This trial not only provides physicians with important additional information about Triumeq, it also builds on the strong body of evidence supporting the efficacy of dolutegravir-based regimens in a broad range of patient populations.”
In terms of adverse events, the data was also favourable towards the Triumeq arm. The drug is currently approved for the treatment of HIV-1 infection.
Sean Murray
Related Content
ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy
GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with …
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, …
China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved …
